Ironwood, AbbVie add 'bloating' and 'discomfort' to Linzess label to reach more IBS-C patients

Ironwood and AbbVie can now add “bloating” and “discomfort” to marketing for irritable bowel syndrome with constipation (IBS-C) drug Linzess, thanks to a supplemental NDA approval from the FDA Thursday.